Cancers (Nov 2022)

A GNAS Gene Mutation’s Independent Expression in the Growth of Colorectal Cancer: A Systematic Review and Meta-Analysis

  • Hafeez Abiola Afolabi,
  • Salzihan Md Salleh,
  • Zaidi Zakaria,
  • Ewe Seng Ch’ng,
  • Siti Norasikin Mohd Nafi,
  • Ahmad Aizat Bin Abdul Aziz,
  • Ahmad Adebayo Irekeola,
  • Yusuf Wada,
  • Sameer Badri Al-Mhanna

DOI
https://doi.org/10.3390/cancers14225480
Journal volume & issue
Vol. 14, no. 22
p. 5480

Abstract

Read online

Globally, colorectal carcinoma CRC is the third most common cancer and the third most common reason for cancer-associated mortality in both genders. The GNAS mutations are significantly linked with poor prognosis and failed treatment outcomes in CRC. A systematic review and meta-analysis of multiple studies executed following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) criteria and registered with PROSPERO (registration number: CRD42021256452). The initial search includes a total of 271 publications; however, only 30 studies that merit the eligibility criteria were eventually chosen. Data analysis via OpenMeta Analyst and comprehensive meta-analysis 3.0 (CMA 3.0) software were used to investigate the prevalence of GNAS gene mutation among CRC patients. The meta-analysis consisted of 10,689 participants with most being males 6068/10,689 (56.8%). Overall, prevalence of GNAS mutations was 4.8% (95% CI: 3.1–7.3) with I2 = 94.39% and (p 2 = 94.00%, (p 2 = 97.93%, (p 2 = 98.10%, (p 2 = 98.%, (p < 0.001). When stratified according to study location, a higher prevalence was observed in Japan (26.8%) while Italy has the lowest (0.4%). Overall prevalence of GNAS gene mutations was 4.8% with codons R201C and R201H being the most mutated, and the results conformed with numerous published studies on GNAS mutation.

Keywords